Barely Significant
← all excerpts

Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial.

EClinicalMedicine · 2024 · PMC11541427 · PMID 39513186

Europe PMCDOI
1
hedged sentence
0.0410
closest p · 0.8× alpha
0.0410
boldest claim

The sentences

failed to reach statistical significancep-value = 0.041actually significant
The observed differences between groups failed to reach statistical significance (one-sided p-value = 0.041).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.